Axol Bioscience
Business Services · United Kingdom · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Roslin Innovation Centre Charnock Bradle...Phone Number
+44 1223751051Website
www.axolbio.comRevenue
$10.4 MillionIndustry
About Axol Bioscience
Axol Bioscience Org Chart
Is Axol Bioscience your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Axol Bioscience, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Axol Bioscience has recently received funding, and reach out quickly before it becomes old news!
Check out if Axol Bioscience is spiking on competitors!
Funding: Get notified immidiatlly once Axol Bioscience has new funding data
Click to see if Axol Bioscience had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Axol Bioscience recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Axol Bioscience
Product Launch: Get notified when Axol Bioscience launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Axol Bioscience
Compare insights from companies similar to Axol Bioscience, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Axol Bioscience is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Axol Bioscience is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Axol Bioscience.
Axol Bioscience financials insights
Gather financial insights about Axol Bioscience, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
Angel/Seed
$1.4M
Unspecified
$3.2M
Unspecified
$4.2M
Axol Bioscience Tech Stack
A closer look at the technologies used by Axol Bioscience
Most Recent Scoops
Axol Bioscience News & Media
ALS TDI Announces New Agreement with Axol Bioscience to Expand Access to ALS Patient iPSC-Derived Cells for Global Research
The ALS Therapy Development Institute (ALS TDI) is proud to announce that a collection of cells derived from ALS patient-derived induced pluripotent stem cell (iPSC) lines will now be made widely available to researchers around the world. [PR.com]Axol Bioscience Acquires Phenocell to Advance Human Disease Models
CAMBRIDGE, England & EDINBURGH, Scotland & GRASSE, France--(BUSINESS WIRE)--Axol Bioscience Ltd. (Axol), a leading induced pluripotent stem cell (iPSC) technology provider for drug discovery, today announced it has fully acquired Phenocell SAS, a pioneer in iPSC-based products and bioassays for skin and retinal disorders. The acquisition extends Axol’s portfolio of iPSC-derived cell models, adding skin and human retinal iPSC-derived cell lines to its existing neuroscience, pain and touch, and cAxol Bioscience Collaborates With StrataStem to Deliver Stem Cell Based ‘Clinical Trial in a Dish’ for Alzheimer’s Disease
CAMBRIDGE, England & EDINBURGH, Scotland & ALDERLEY PARK, England--(BUSINESS WIRE)--Axol Bioscience Ltd. (Axol), a leading pluripotent stem cell technology provider for drug discovery has signed an exclusive agreement with StrataStem to access and commercialize its extensive collection of Alzheimer’s Disease (AD) patient samples. Harnessing its stem cell expertise, Axol will reprogram these patient samples into induced Pluripotent Stem Cells (iPSCs) that can then be differentiated into a wide rAxol Bioscience Introduces CiPA-Validated Human Stem Cell-Derived Ventricular Cardiomyocytes to Help Improve Drug Discovery
CAMBRIDGE, England & EDINBURGH, Scotland--(BUSINESS WIRE)--Axol Bioscience Ltd. (Axol), an established provider of iPSC-derived cells, media, and characterization services for life science discovery, today announced that its human induced pluripotent stem cell (iPSC)-derived ventricular cardiomyocytes have undergone comprehensive in vitro pro-arrhythmia assay (CiPA) validation. Using this assay, the cells were shown to be suitable for measuring cardiotoxicity, offering scientists a robust cardi
Top Business Services Companies
Frequently Asked Questions Regarding Axol Bioscience
Axol Bioscience specialize in the supply of human cell culture systems and custom services for disease modeling and drug discovery... Read More